Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer.
Journal of Clinical Oncology.
Times cited: 96
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): A randomised, double-blind phase 3 trial.
The Lancet Oncology.
Times cited: 146